| Literature DB >> 24466109 |
Liang Shi1, Sarah Nechuta2, Yu-Tang Gao3, Ying Zheng4, Tsogzolmaa Dorjgochoo2, Jie Wu2, Qiuyin Cai2, Wei Zheng2, Wei Lu4, Xiao Ou Shu2.
Abstract
BACKGROUND: Few studies have investigated vitamin D status in association with modifiable lifestyle factors and clinical characteristics among breast cancer patients, with no studies among Chinese women, who may be at higher risk of vitamin D deficiency. We aimed to evaluate circulating 25-hydroxyvitamin D (25(OH)D) levels in association with clinical and lifestyle factors among 1,940 Chinese breast cancer patients.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24466109 PMCID: PMC3897707 DOI: 10.1371/journal.pone.0086467
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Select Cohort Characteristics by Vitamin D Status (n = 1,940).
| 25(OH)D levels (nmol/L) | ||||
| Deficient (<30) N = 450 | Insufficient (30–50) N = 938 | Sufficient (>50) N = 552 | P value | |
|
| 50.3± (8.1) | 50.2± (8.5) | 48.8± (7.9) | <0.01 |
|
| ||||
| None/elementary | 45 (10.0) | 97 (10.3) | 47 (8.5) | |
| Middle school | 193 (42.9) | 426 (45.4) | 239 (43.3) | |
| High school | 159 (35.3) | 307 (32.7) | 198 (35.9) | |
| ≥College | 53 (11.8) | 108 (11.5) | 68 (12.3) | 0.49 |
|
| ||||
| <10000 | 140 (31.1) | 294 (31.3) | 188 (34.1) | |
| 10000–19999 | 159 (35.3) | 380 (40.5) | 195 (35.3) | |
| 20000–29999 | 80 (17.8) | 128 (13.7) | 92 (16.7) | |
| ≥30000 | 71 (15.8) | 136 (14.5) | 77 (14.0) | 0.25 |
|
| ||||
| Professional | 119 (26.5) | 225 (24.0) | 138 (25.1) | |
| Clerical | 107 (23.8) | 223 (23.8) | 144 (26.1) | |
| Manual worker/housewife | 223 (49.7) | 489 (52.2) | 269 (48.8) | 0.98 |
|
| ||||
| Winter | 120 (26.7) | 207 (22.1) | 112 (20.3) | |
| Spring | 133 (29.6) | 266 (28.4) | 132 (23.9) | |
| Summer | 107 (23.8) | 238 (25.4) | 149 (27.0) | |
| Autumn | 90 (20.0) | 227 (24.2) | 159 (28.8) | <0.01 |
|
| ||||
| ≤1 | 346 (76.9) | 690 (73.6) | 406 (73.6) | |
| 1–<6 | 86 (19.1) | 196 (20.9) | 117 (21.2) | |
| ≥6 | 18 (4.0) | 52 (5.5) | 29 (5.2) | 0.22 |
|
| ||||
| SBCS I | 257 (57.1) | 488 (52.0) | 299 (54.2) | |
| SBCS II | 193 (42.9) | 450 (48.0) | 253 (45.8) | 0.20 |
|
| ||||
| Premenopausal | 265 (58.9) | 557 (59.4) | 366 (66.3) | |
| Postmenopausal | 185 (41.1) | 381 (40.6) | 186 (33.7) | 0.02 |
|
| ||||
| 0–I | 128 (28.4) | 279 (29.7) | 158 (28.6) | |
| II | 231 (51.3) | 496 (52.9) | 282 (51.1) | |
| III–IV | 49 (10.9) | 94 (10) | 43 (7.8) | |
| Unknown | 42 (9.3) | 69 (7.4) | 69 (12.5) | 0.49 |
|
| ||||
| ER+/PR+ | 198 (44.0) | 404 (43.1) | 248 (44.9) | |
| ER+/PR- or ER−/PR+ | 74 (16.4) | 152 (16.2) | 91 (16.5) | |
| ER−/PR- | 85 (18.9) | 215 (22.9) | 111 (20.1) | |
| Unknown | 93 (20.7) | 167 (17.8) | 102 (18.5) | 0.57 |
Based on Chi-square test for categorical variables and Kruskal-Wallis Test for continuous variables.
Excludes three women missing occupation.
Prevalence ORs and 95% CIs for associations of anthropometric factors with vitamin D statusa among breast cancer patients (n = 1,940).
| Adjusted for age and season | Further adjusted | ||||||||||
| Sufficient | Insufficient (30–50) N = 938 | Deficient (<30) N = 450 | Insufficient (30–50) N = 938 | Deficient (<30) N = 450 | |||||||
| NO. | NO. | OR | (95% CI) | NO. | OR | (95% CI) | OR | (95% CI) | OR | (95% CI) | |
|
| |||||||||||
| <73.0 | 125 | 209 | 1.00 | (reference) | 103 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| 73.0–<79.0 | 167 | 245 | 0.83 | (0.61,1.12) | 97 | 0.66 | (0.46,0.96) | 0.81 | (0.60,1.10) | 0.66 | (0.46,0.96) |
| 79.0–<85.0 | 132 | 232 | 0.96 | (0.70,1.31) | 112 | 0.94 | (0.65,1.37) | 0.94 | (0.68,1.29) | 0.96 | (0.66,1.40) |
| ≥85.0 | 128 | 252 | 1.02 | (0.74,1.41) | 137 | 1.14 | (0.78,1.67) | 0.98 | (0.70,1.37) | 1.18 | (0.80,1.74) |
| Ptrend | 0.66 | 0.16 | 0.83 | 0.12 | |||||||
|
| |||||||||||
| <0.78 | 106 | 194 | 1.00 | (reference) | 87 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| 0.78–<0.82 | 160 | 237 | 0.78 | (0.57,1.07) | 98 | 0.73 | (0.50,1.08) | 0.77 | (0.56,1.05) | 0.77 | (0.52,1.13) |
| 0.82–<0.86 | 150 | 230 | 0.78 | (0.56,1.07) | 116 | 0.90 | (0.61,1.32) | 0.76 | (0.55,1.05) | 0.94 | (0.64,1.39) |
| ≥0.86 | 136 | 275 | 0.96 | (0.69,1.33) | 148 | 1.18 | (0.80,1.74) | 0.91 | (0.65,1.28) | 1.27 | (0.85,1.91) |
| Ptrend | 0.95 | 0.16 | 0.71 | 0.09 | |||||||
|
| |||||||||||
| <21.5 | 143 | 229 | 1.00 | (reference) | 99 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| 21.5–<23.5 | 146 | 225 | 0.93 | (0.69,1.25) | 114 | 1.09 | (0.76,1.57) | 0.91 | (0.68,1.23) | 1.10 | (0.77,1.59) |
| 23.5–<25.9 | 147 | 249 | 0.99 | (0.74,1.33) | 107 | 0.99 | (0.69,1.42) | 0.97 | (0.72,1.32) | 1.00 | (0.69,1.44) |
| ≥25.9 | 116 | 234 | 1.14 | (0.83,1.57) | 129 | 1.47 | (1.01,2.13) | 1.13 | (0.82,1.56) | 1.50 | (1.03,2.20) |
| Ptrend | 0.39 | 0.08 | 0.43 | 0.07 | |||||||
|
| |||||||||||
| <25 | 384 | 633 | 1.00 | (reference) | 282 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| 25–<30 | 147 | 257 | 1.01 | (0.79,1.29) | 143 | 1.28 | (0.96,1.69) | 1.00 | (0.78,1.28) | 1.29 | (0.97,1.72) |
| ≥30 | 21 | 47 | 1.21 | (0.71,2.07) | 24 | 1.40 | (0.76,2.59) | 1.21 | (0.70,2.08) | 1.41 | (0.76,2.63) |
| Ptrend | 0.62 | 0.07 | 0.66 | 0.07 | |||||||
|
| |||||||||||
| <23 | 253 | 388 | 1.00 | (reference) | 181 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| 23–<27.5 | 245 | 425 | 1.08 | (0.86,1.36) | 203 | 1.11 | (0.85,1.46) | 1.07 | (0.85,1.35) | 1.12 | (0.85,1.47) |
| ≥27.5 | 54 | 124 | 1.35 | (0.94,1.95) | 65 | 1.53 | (1.01,2.34) | 1.35 | (0.93,1.97) | 1.57 | (1.02,2.42) |
| Ptrend | 0.13 | 0.07 | 0.15 | 0.06 | |||||||
Vitamin D status was based on measured circulating 25(OH)D levels in nmol/L. Women missing anthropometric data were excluded: waist (n = 1), WHR (n = 3), BMI (n = 2).
Reference group.
Additionally adjusted for (where applicable) education level, SBCS phase, total physical activity (MET-hours/day), menopausal status, TNM stage, tumor estrogen/progesterone receptor status.
Prevalence ORs and 95% CIs for associations of physical activity, smoking, and alcohol drinking with vitamin D statusa among breast cancer patients (n = 1,940).
| Adjusted for age and season | Further adjusted | ||||||||||
| Sufficient | Insufficient (30–50) N = 938 | Deficient (<30) N = 450 | Insufficient (30–50) N = 938 | Deficient (<30) N = 450 | |||||||
| NO. | NO. | OR | (95% CI) | NO. | OR | (95% CI) | OR | (95% CI) | OR | (95% CI) | |
|
| |||||||||||
| <7.65 | 135 | 221 | 1.00 | (reference) | 129 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| 7.65–<10.6 | 131 | 236 | 1.05 | (0.78,1.43) | 116 | 0.88 | (0.62,1.25) | 1.03 | (0.76,1.40) | 0.84 | (0.59,1.20) |
| 10.6–<13.5 | 149 | 236 | 0.91 | (0.67,1.23) | 101 | 0.66 | (0.46,0.94) | 0.87 | (0.64,1.18) | 0.65 | (0.45,0.93) |
| ≥13.5 | 137 | 245 | 0.98 | (0.72,1.33) | 104 | 0.69 | (0.48,1.00) | 0.94 | (0.69,1.29) | 0.69 | (0.48,1.00) |
| Ptrend | 0.67 | 0.02 | 0.48 | 0.02 | |||||||
|
| |||||||||||
| none | 426 | 695 | 1.00 | (reference) | 344 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| <30 | 84 | 168 | 1.10 | (0.82,1.48) | 79 | 1.00 | (0.70,1.41) | 1.10 | (0.82,1.49) | 1.00 | (0.70,1.43) |
| ≥30 | 39 | 74 | 0.96 | (0.63,1.47) | 26 | 0.64 | (0.38,1.10) | 0.96 | (0.62,1.48) | 0.69 | (0.40,1.20) |
| Ptrend | 0.89 | 0.20 | 0.86 | 0.31 | |||||||
|
| |||||||||||
| <30 | 120 | 162 | 1.00 | (reference) | 80 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| 30–59 | 141 | 253 | 1.25 | (0.91,1.71) | 122 | 1.20 | (0.82,1.75) | 1.18 | (0.85,1.65) | 1.04 | (0.70,1.54) |
| 59–90 | 177 | 277 | 1.05 | (0.77,1.44) | 145 | 1.11 | (0.76,1.60) | 0.98 | (0.70,1.37) | 0.91 | (0.61,1.35) |
| ≥90 | 114 | 246 | 1.43 | (1.03,2.00) | 103 | 1.20 | (0.80,1.79) | 1.32 | (0.92,1.89) | 1.00 | (0.65,1.54) |
| Ptrend | 0.11 | 0.54 | 0.30 | 0.81 | |||||||
|
| |||||||||||
| none | 334 | 626 | 1.00 | (reference) | 341 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| <30 | 41 | 36 | 0.52 | (0.33,0.84) | 14 | 0.37 | (0.20,0.70) | 0.53 | (0.33,0.87) | 0.39 | (0.20,0.73) |
| 30–59 | 73 | 133 | 1.05 | (0.76,1.45) | 41 | 0.58 | (0.38,0.88) | 1.06 | (0.76,1.48) | 0.59 | (0.39,0.91) |
| ≥60 | 104 | 143 | 0.80 | (0.60,1.08) | 54 | 0.55 | (0.38,0.80) | 0.84 | (0.62,1.14) | 0.56 | (0.38,0.82) |
| Ptrend | 0.26 | <0.01 | 0.44 | <0.01 | |||||||
|
| |||||||||||
| <30 | 44 | 68 | 1.00 | (reference) | 48 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| 30–59 | 137 | 211 | 0.96 | (0.62,1.49) | 106 | 0.69 | (0.42,1.12) | 0.94 | (0.60,1.46) | 0.68 | (0.41,1.11) |
| 60–90 | 175 | 288 | 1.00 | (0.65,1.53) | 150 | 0.74 | (0.46,1.18) | 0.97 | (0.63,1.50) | 0.74 | (0.46,1.20) |
| ≥90 | 196 | 371 | 1.16 | (0.76,1.76) | 146 | 0.65 | (0.40,1.03) | 1.12 | (0.73,1.73) | 0.66 | (0.41,1.07) |
| Ptrend | 0.22 | 0.16 | 0.29 | 0.26 | |||||||
|
| |||||||||||
| <30 | 42 | 63 | 1.00 | (reference) | 47 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| 30–59 | 127 | 202 | 1.03 | (0.66,1.62) | 100 | 0.68 | (0.41,1.12) | 1.00 | (0.63,1.58) | 0.67 | (0.40,1.10) |
| 60–119 | 252 | 404 | 1.00 | (0.65,1.53) | 202 | 0.66 | (0.42,1.05) | 0.97 | (0.63,1.50) | 0.67 | (0.42,1.07) |
| ≥120 | 131 | 269 | 1.25 | (0.80,1.96) | 101 | 0.62 | (0.38,1.02) | 1.22 | (0.77,1.93) | 0.64 | (0.38,1.07) |
| Ptrend | 0.22 | 0.12 | 0.27 | 0.20 | |||||||
|
| |||||||||||
| Never | 545 | 909 | 1.00 | (reference) | 434 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| Yes | 7 | 29 | 2.40 | (1.04,5.54) | 16 | 2.72 | (1.10,6.71) | 2.50 | (1.07,5.84) | 2.78 | (1.11,6.95) |
|
| |||||||||||
| Never | 534 | 895 | 1.00 | (reference) | 427 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| Yes | 18 | 43 | 1.45 | (0.82,2.54) | 23 | 1.62 | (0.86,3.05) | 1.51 | (0.85,2.66) | 1.70 | (0.89,3.22) |
Vitamin D status was based on measured circulating 25(OH)D levels in nmol/L. Models with exercise duration exclude five women missing data on exercise duration.
Reference group.
Additionally adjusted for education level, SBCS phase, BMI in quartiles, menopausal status, TNM stage, tumor estrogen/progesterone receptor status and total physical activity (MET-hours/day) (where applicable).
Additionally adjusted for non-exercise METs.
Did not include walking for exercise.
Additionally adjusted for exercise duration, walking duration (where applicable), and biking duration (where applicable).
Did not include biking for exercise.
Walking (not for exercise) and biking (not for exercise) duration.
Additionally adjusted for exercise duration.
Includes walking and biking for transportation and exercise duration.
Prevalence ORs and 95% CIs for the association of supplement use, diabetes and hypertension with vitamin Da status among breast cancer patients (n = 896)b.
| Adjusted for age and season | Further adjusted | ||||||||||
| Sufficient | Insufficient (30–50) N = 938 | Deficient (<30) N = 450 | Insufficient (30–50) N = 938 | Deficient (<30) N = 450 | |||||||
| NO. | NO. | OR | (95% CI) | NO. | OR | (95% CI) | OR | (95% CI) | OR | (95% CI) | |
|
| |||||||||||
| No | 199 | 375 | 1.00 | (reference) | 166 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| Yes | 54 | 75 | 0.72 | (0.48,1.07) | 27 | 0.63 | (0.37,1.06) | 0.71 | (0.47,1.08) | 0.61 | (0.36,1.05) |
|
| |||||||||||
| No | 234 | 414 | 1.00 | (reference) | 176 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| Yes | 19 | 36 | 0.95 | (0.52,1.72) | 17 | 1.13 | (0.56,2.31) | 1.01 | (0.55,1.88) | 1.18 | (0.57,2.45) |
|
| |||||||||||
| No | 221 | 393 | 1.00 | (reference) | 185 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| Yes | 32 | 57 | 0.90 | (0.56,1.46) | 8 | 0.27 | (0.12,0.61) | 0.87 | (0.52,1.44) | 0.25 | (0.11,0.58) |
|
| |||||||||||
| No | 238 | 424 | 1.00 | (reference) | 182 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| Yes | 15 | 26 | 0.80 | (0.41,1.59) | 11 | 0.87 | (0.38,2.02) | 0.84 | (0.42,1.68) | 0.85 | (0.36,2.00) |
|
| |||||||||||
| No | 218 | 344 | 1.00 | (reference) | 148 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| Yes | 35 | 106 | 1.79 | (1.15,2.79) | 45 | 1.97 | (1.16,3.34) | 1.91 | (1.20,3.02) | 2.01 | (1.16,3.47) |
Vitamin D status was based on measured levels in nmol/L.
This table includes SBCS participants with information collected on supplements, diabetes and hypertension history.
Reference group.
Additionally adjusted for education level, total physical activity (MET-hours/day), BMI in quartiles, menopausal status, TNM stage, and tumor estrogen/progesterone receptor status.